Crossmark

A randomized placebo-controlled phase I clinical trial to evaluate the immunomodulatory activities of Atractylodes lancea (Thunb) DC. in healthy Thai subjects

Crossref DOI link: https://doi.org/10.1186/s12906-020-03199-6

Published Online: 2021-02-12

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kulma, Inthuon

Panrit, Luxsana

Plengsuriyakarn, Tullayakorn

Chaijaroenkul, Wanna

Warathumpitak, Siriprapa

Na-Bangchang, Kesara
Funding

Funding for this research was provided by:

Thammasat University (2020-01)

Thailand Research Fund (PHD/0096/2560)

National Research Council of Thailand (820/2563)
License Information

Text and Data Mining valid from 2021-02-12

Version of Record valid from 2021-02-12
More Information

Article History

Received: 12 October 2020

Accepted: 28 December 2020

First Online: 12 February 2021

Ethics approval and consent to participate

: The clinical study protocol was approved by the Human research Ethics Committee of Thammasat University, Thailand (No. 019/2561). Written informed consents for study participation was obtained from all subjects before study.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below